These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 9191252)

  • 1. The structure and function of the novel MHC class II molecule, HLA-DM.
    Gruneberg U; Van Ham SM; Malcherek G; Broker I; Melms A; Trowsdale J
    Biochem Soc Trans; 1997 May; 25(2):208S. PubMed ID: 9191252
    [No Abstract]   [Full Text] [Related]  

  • 2. The structure of an intermediate in class II MHC maturation: CLIP bound to HLA-DR3.
    Ghosh P; Amaya M; Mellins E; Wiley DC
    Nature; 1995 Nov; 378(6556):457-62. PubMed ID: 7477400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rheumatoid arthritis (RA)-associated HLA-DR alleles form less stable complexes with class II-associated invariant chain peptide than non-RA-associated HLA-DR alleles.
    Patil NS; Pashine A; Belmares MP; Liu W; Kaneshiro B; Rabinowitz J; McConnell H; Mellins ED
    J Immunol; 2001 Dec; 167(12):7157-68. PubMed ID: 11739539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HLA-DO increases bacterial superantigen binding to human MHC molecules by inhibiting dissociation of class II-associated invariant chain peptides.
    Pezeshki AM; Azar GA; Mourad W; Routy JP; Boulassel MR; Denzin LK; Thibodeau J
    Hum Immunol; 2013 Oct; 74(10):1280-7. PubMed ID: 23756162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Variation in HLA-DM expression influences conversion of MHC class II alpha beta:class II-associated invariant chain peptide complexes to mature peptide-bound class II alpha beta dimers in a normal B cell line.
    Ramachandra L; Kovats S; Eastman S; Rudensky AY
    J Immunol; 1996 Mar; 156(6):2196 - 2204. PubMed ID: 8690909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mediation by HLA-DM of dissociation of peptides from HLA-DR.
    Sloan VS; Cameron P; Porter G; Gammon M; Amaya M; Mellins E; Zaller DM
    Nature; 1995 Jun; 375(6534):802-6. PubMed ID: 7596415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HLA-DO is an intracellular class II molecule with distinctive thymic expression.
    Douek DC; Altmann DM
    Int Immunol; 1997 Mar; 9(3):355-64. PubMed ID: 9088974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HLA-DM and HLA-DO, key regulators of MHC-II processing and presentation.
    Mellins ED; Stern LJ
    Curr Opin Immunol; 2014 Feb; 26():115-22. PubMed ID: 24463216
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antigen presentation: Kissing cousins exchange CLIP.
    Sanderson F; Trowsdale J
    Curr Biol; 1995 Dec; 5(12):1372-6. PubMed ID: 8749389
    [No Abstract]   [Full Text] [Related]  

  • 10. Aberrant intermolecular disulfide bonding in a mutant HLA-DM molecule: implications for assembly, maturation, and function.
    Busch R; Doebele RC; von Scheven E; Fahrni J; Mellins ED
    J Immunol; 1998 Jan; 160(2):734-43. PubMed ID: 9551909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel mutants define genes required for the expression of human histocompatibility leukocyte antigen DM: evidence for loci on human chromosome 6p.
    Fling SP; Rak J; Muczynski KA; Arp B; Pious D
    J Exp Med; 1997 Nov; 186(9):1469-80. PubMed ID: 9348304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A common set of factors control the expression of the MHC class II, invariant chain, and HLA-DM genes.
    Boss JM
    Microbes Infect; 1999 Sep; 1(11):847-53. PubMed ID: 10614001
    [No Abstract]   [Full Text] [Related]  

  • 13. Point mutations in or near the antigen-binding groove of HLA-DR3 implicate class II-associated invariant chain peptide affinity as a constraint on MHC class II polymorphism.
    Doebele RC; Pashine A; Liu W; Zaller DM; Belmares M; Busch R; Mellins ED
    J Immunol; 2003 May; 170(9):4683-92. PubMed ID: 12707347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quality control of MHC class II associated peptides by HLA-DM/H2-M.
    Vogt AB; Arndt SO; Hämmerling GJ; Kropshofer H
    Semin Immunol; 1999 Dec; 11(6):391-403. PubMed ID: 10625593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human histocompatibility leukocyte antigen (HLA)-DM edits peptides presented by HLA-DR according to their ligand binding motifs.
    van Ham SM; Grüneberg U; Malcherek G; Bröker I; Melms A; Trowsdale J
    J Exp Med; 1996 Nov; 184(5):2019-24. PubMed ID: 8920889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cutting edge: HLA-DM functions through a mechanism that does not require specific conserved hydrogen bonds in class II MHC-peptide complexes.
    Zhou Z; Callaway KA; Weber DA; Jensen PE
    J Immunol; 2009 Oct; 183(7):4187-91. PubMed ID: 19767569
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impaired antigen presentation by murine I-Ad class II MHC molecules expressed in normal and HLA-DM-defective human B cell lines.
    Weenink S; Averdunk H; Boston T; Boswarva V; Guery JC; Adorini L; Mellins E; McCluskey J; Gautam AM
    Int Immunol; 1997 Jun; 9(6):889-96. PubMed ID: 9199972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Negative regulation by HLA-DO of MHC class II-restricted antigen processing.
    Denzin LK; Sant'Angelo DB; Hammond C; Surman MJ; Cresswell P
    Science; 1997 Oct; 278(5335):106-9. PubMed ID: 9311912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Editing of the HLA-DR-peptide repertoire by HLA-DM.
    Kropshofer H; Vogt AB; Moldenhauer G; Hammer J; Blum JS; Hämmerling GJ
    EMBO J; 1996 Nov; 15(22):6144-54. PubMed ID: 8947036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The intracellular transport of MHC class II molecules in the absence of HLA-DM.
    Green JM; DeMars R; Xu X; Pierce SK
    J Immunol; 1995 Oct; 155(8):3759-68. PubMed ID: 7561080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.